Pharyngitis Therapeutics Market: Comprehensive Analysis and Future Estimations 2026 Appraised By Global Players Genentech Inc., Adamas Pharmaceutical Inc., PLIVA HRVATSKA d.o.o., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Mylan N.V.

Pharyngitis, commonly referred to as sore throat, causes inflammation of pharynx located behind the throat. Pharyngitis is caused by bacterial or viral infections and cases of pharyngitis are majorly observed in colder months of the year. Measles, adenovirus, chickenpox, croup, whooping cough, and group A streptococcus are the major causes of pharyngitis. Pharyngitis is also commonly caused by viral infections such as common cold, influenza, and mononucleosis. According to the Centers for Disease Control and Prevention (CDC), amoxicillin and penicillin are the most commonly prescribed treatments for sore throat.

Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/2001

Pharyngitis treatment is majorly based on the symptoms, depending the cause of pharyngitis for example, bacterial, fungal, and herpes simplex infections. The common symptoms of pharyngitis include sneezing, runny nose, headache, cough, fatigue, body aches, chills, and fever. Additionally, strep throat condition also occurs, which may lead to difficulty in swallowing, loss of appetite, nausea, fever, loss of taste, and swollen lymph nodes. Pain medication such as NSAIDs and acetaminophen are used to reduce the pain associated with pharyngitis. Besides, Aspirin is also used by adults, however, not recommended for children due to risk of occurrence of Reye syndrome.

Pharyngitis Therapeutics Market Dynamics:

According to the study published in 2016, by the Centers for Disease Control and Prevention (CDC) and Pew Charitable Trusts, doctors are often prescribing the wrong antibiotics, which concluded that only 52% of the 44 million antibiotic prescribed for sinus infections, middle ear infections, and pharyngitis are the first-line drugs. Furthermore, in 2017, the World Health Organization (WHO) released a report suggesting that there is a serious lack of new antibiotics in development, underscoring that antibiotic resistance is a global health emergency set to undermine the decades of progress in modern medicine.

Therefore, manufactures are increasingly focusing on research and development for new discovery of antibiotics or any other therapeutic drugs to treat pharyngitis. For instance, Innovative Med Concepts, Inc. is in the process of developing a promising treatment for pharyngitis i.e the company’s second novel product NRP-1—a proprietary throat spray—is designed to treat viral pharyngitis, which is expected to serve the large unmet medical needs and cause of most cases of pharyngitis. NRP-1 will also provide the required relief for cancer patients undergoing head and neck radiation plagued with disabling oral mucositis/pharyngitis. This spray delivers medication, which then adheres to the posterior pharynx despite repeated swallows and saliva.Pharyngitis

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/pharyngitis-therapeutics-market-2001

Therapeutics Market - Regional Insights

North America accounted for the largest share in the global pharyngitis therapeutics market, followed by Europe market in 2016. This is attributed to increasing prevalence of pharyngitis in North America. According to data published in American Family Physician Journal in 2009, pharyngitis is diagnosed in 11 million people in outpatient settings, each year in the U.S.

Furthermore, several pharmaceutical and biotechnological companies are focusing on expanding in the Asia Pacific region, to maximize their R&D efforts, as the Asia Pacific region provides low capital investment in research and development due to lower operational cost and highly efficient technicians. Increasing government investment in research and development is also expected to foster growth of the pharyngitis therapeutics market in Asia Pacific. As Group A Streptococcus is the most common disease caused in settings of poverty, where transmission of an organism is possible due to the poor living conditions. Hence Asia Pacific region provides a high opportunity for drug manufacturers in pharyngitis therapeutics market.

Pharyngitis Therapeutics Market - Competitive Analysis

Major players operating in the market include Genentech Inc., Adamas Pharmaceutical Inc., PLIVA HRVATSKA d.o.o., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Mylan N.V., GSK group of companies, Teva Pharmaceutical Industries Ltd., and AbbVie Inc.

Pharyngitis Therapeutics Market - Taxonomy:

By Source of Infection:
Viral
Bacterial

By Drug Class:
Antiviral Drugs
Antibacterial Drugs
Anti-inflammatory Drugs
Topical Anesthetics Drugs

By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region:
North America
Latin America
Europe
Asia Pacific
Middle East
Africa

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2001

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.